Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license to further develop and worldwide commercialize ChemoCentryx's investigational medicine CCX354, across the globe, indicated for rheumatoid arthritis (RA) treatment.
Subscribe to our email newsletter
CCX354 is a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).
ChemoCentryx reported positive results from a Phase II clinical trial with CCX354 which evaluated the safety, tolerability, clinical and biological activity of this compound in patients with RA.
As per the agreement with GSK, ChemoCentryx will receive an option exercise fee of $25m and will be eligible for further regulatory and sales milestone payments.
GSK will now be solely responsible for funding further clinical development and commercialization for CCX354 worldwide.